Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.

McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG.

J Virol. 2011 Jan;85(1):366-77. doi: 10.1128/JVI.01861-10. Epub 2010 Oct 27.

2.

Subunit and virus-like particle vaccine approaches for respiratory syncytial virus.

Morrison TG, Walsh EE.

Curr Top Microbiol Immunol. 2013;372:285-306. doi: 10.1007/978-3-642-38919-1_14. Review.

PMID:
24362695
3.

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Collins PL, Melero JA.

Virus Res. 2011 Dec;162(1-2):80-99. doi: 10.1016/j.virusres.2011.09.020. Epub 2011 Sep 22. Review.

4.

Structure and function of respiratory syncytial virus surface glycoproteins.

McLellan JS, Ray WC, Peeples ME.

Curr Top Microbiol Immunol. 2013;372:83-104. doi: 10.1007/978-3-642-38919-1_4. Review.

5.

Gene-based vaccine approaches for respiratory syncytial virus.

Loomis RJ, Johnson PR.

Curr Top Microbiol Immunol. 2013;372:307-24. doi: 10.1007/978-3-642-38919-1_15. Review.

PMID:
24362696
6.

Strategic priorities for respiratory syncytial virus (RSV) vaccine development.

Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS.

Vaccine. 2013 Apr 18;31 Suppl 2:B209-15. doi: 10.1016/j.vaccine.2012.11.106. Review.

7.

Targeting RSV with vaccines and small molecule drugs.

Costello HM, Ray WC, Chaiwatpongsakorn S, Peeples ME.

Infect Disord Drug Targets. 2012 Apr;12(2):110-28. Review.

8.

Respiratory syncytial virus vaccine development.

Murata Y.

Clin Lab Med. 2009 Dec;29(4):725-39. doi: 10.1016/j.cll.2009.07.004. Review.

9.

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Acosta PL, Caballero MT, Polack FP.

Clin Vaccine Immunol. 2015 Dec 16;23(3):189-95. doi: 10.1128/CVI.00609-15. Review.

10.

[Research Progress in the F Gene and Protein of the Respiratory Syncytial Virus].

Zhang F, Xie Z.

Bing Du Xue Bao. 2015 Mar;31(2):201-6. Review. Chinese.

PMID:
26164949
11.

Modulation of the host immune response by respiratory syncytial virus proteins.

Schmidt ME, Varga SM.

J Microbiol. 2017 Mar;55(3):161-171. doi: 10.1007/s12275-017-7045-8. Epub 2017 Feb 28. Review.

PMID:
28243940
12.

Novel antigens for RSV vaccines.

Graham BS, Modjarrad K, McLellan JS.

Curr Opin Immunol. 2015 Aug;35:30-8. doi: 10.1016/j.coi.2015.04.005. Epub 2015 Jun 10. Review.

13.

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Broadbent L, Groves H, Shields MD, Power UF.

Influenza Other Respir Viruses. 2015 Jul;9(4):169-78. doi: 10.1111/irv.12313. Review.

14.

Current concepts and progress in RSV vaccine development.

Guvenel AK, Chiu C, Openshaw PJ.

Expert Rev Vaccines. 2014 Mar;13(3):333-44. doi: 10.1586/14760584.2014.878653. Epub 2014 Jan 9. Review.

PMID:
24405366
15.

Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.

Rey-Jurado E, Kalergis AM.

Int J Mol Sci. 2017 Mar 4;18(3). pii: E556. doi: 10.3390/ijms18030556. Review.

16.

Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

McLellan JS.

Curr Opin Virol. 2015 Apr;11:70-5. doi: 10.1016/j.coviro.2015.03.002. Epub 2015 Mar 26. Review.

17.
18.

The RSV fusion receptor: not what everyone expected it to be.

Mastrangelo P, Hegele RG.

Microbes Infect. 2012 Nov;14(13):1205-10. doi: 10.1016/j.micinf.2012.07.015. Epub 2012 Jul 31. Review.

PMID:
22884716
19.
20.

Supplemental Content

Support Center